Steve D. Wilton

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 862 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Maria Kinali, Virginia Arechavala‐Gomeza, Lucy Feng et al. · The Lancet Neurology · 2009 · 639 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology

J. Alter, Fang Lou, Adam Rabinowitz et al. · Nature Medicine · 2006 · 492 citations

Pharmacy, Molecular Medicine, Neuroscience +16

Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube.

Steve D. Wilton, D.V. Cousins · Genome Research · 1992 · 304 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression

Céline Vanderplanck, Eugénie Ansseau, Sébastien Charron et al. · PLoS ONE · 2011 · 209 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15